AB1408-HPR INFLUENCE OF WEIGHT AND LIPID PROFILE IN RHEUMATIC PATIENTS WHO CHANGE FROM BIOLOGICAL THERAPY
Authors: Rocio Segura, Maria del Carmen Abalos-Aguilera, Alejandra M. Patio-Trives, Juan Vacas, Joaquin Sosa, Celestino Gil, Maria del Rosario Navarro, Mara del Carmen Castro Villegas, Rafaela Ortega Castro, Jerusalem Calvo Gutierrez, Desiree Ruiz, Montserrat Romero-Gmez, Ladehesa Pineda Lourdes, Alejandro Escudero Contreras, Eduardo Collantes-Estvez, Font Ugalde Pilar, Luis Jurado
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> The lack of efficacy of biological therapies in rheumatic patients causes a change of treatment, usually to another biological therapy. A significant number of studies have been published in relation to the reasons that cause this inefficacy, <sup>(1,2,3)</sup>; however, no studies have evaluated the involvement of the weight and lipid profile of patients in this process. <h3>Objectives</h3> To analyze the influence of weight and lipid profile in the relapse and change of biological therapy. <h3>Methods</h3> Retrospective-descriptive study. Rheumatic patients in treatment with biological therapies were recruited from January 2016 to December 2018. Sociodemographic data were collected (age and sex), along with anthropometric variables (weight, height, waist circumference and hip perimeter), toxic habits, comorbidities and variables related to the treatment. Associations between variables were analyzed using a Chi-square and T student. P-values &lt; 0.05 were considered statistically significant. The spss v.19 program was used for data analysis. <h3>Results</h3> Two hundred and nine patients were enrolled, of which 80 (38.3%) were male and 129 (61.7%) were female. The mean age (SD) was 48.9 12.8 years. One hundred and twenty patients (57.4%) suffered rheumatoid arthritis, 35 (16.7%) spondylitis, 29 (13.9%) psoriatic arthritis and 10 (4.8%) spondyloarthritis. One hundred and fifty-three (73.2%) had not switches of biological therapy, 51 (24.4%) switched of biological therapy once and 5 (2.4%) three or more times. Statistically significant differences were found in the obese males who switched of biological therapy in relation to obese males who not switched (35.6% vs. 11.1%). Accordingly, the percentage of patients with hyperlipemia that switched of biological therapy was significantly higher than those who did not (29.4% vs. 13.1%). The years of evolution and diagnosis we also involved, so that patients with more years of evolution and more years from the diagnosis had a higher percentage of switched (p = 0.006 IC 95% -17.22, - 0.96 and p = 0.042 -18, 32; -037 respectively). <h3>Conclusion</h3> Being obese male and with hyperlipidemia could be a risk factor that would condition the lack of response to a biological therapy and thus the need of switching to another. <h3>References</h3> [1] Glintborg B1, stergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013Jul;72(7):1149-55. doi: 10.1136/annrheumdis-2012-201933. Epub 2012 Aug 31. [2] Navarro-Compn V, Plasencia-Rodrguez C, de Miguel E, Diaz Del Campo P, Balsa A, Gratacs J. Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open. 2017 Oct 10;3(2):e000524. doi: 10.1136/rmdopen-2017-000524. eCollection 2017. [3] Ganzetti G, Campanati A, Bettacchi A, Brandozzi G, Brisigotti V, Bugatti L, Cataldi I, Filosa G, Giacchetti A, Lemme G, Morresi L, Nicolini M, Postacchini V, Ricotti G, Rosa L, Simonacci M, Offidani A. Switching from a biological therapy to another biologic agent in psoriatic patients: the experience of PsOMarche group. G Ital Dermatol Venereol. 2018 Feb;153(1):5-10. doi: 10.23736/S0392-0488.16.05463-8. Epub 2016 Nov 15. <h3>Disclosure of Interests</h3> Rocio Segura: None declared, Maria del Carmen Abalos-Aguilera: None declared, Alejandra M. Patio-Trives: None declared, juan vacas: None declared, Joaquin Sosa: None declared, Celestino Gil: None declared, Maria del Rosario Navarro: None declared, Mara del Carmen Castro Villegas Paid instructor for: MSD, Abbvie, Pfizer, Janssen, Lilly, Roche, Rafaela Ortega Castro: None declared, Jerusalem Calvo Gutierrez: None declared, Desiree Ruiz: None declared, Montserrat Romero-Gmez: None declared, Ladehesa Pineda Lourdes: None declared, Alejandro Escudero Contreras: None declared, Eduardo Collantes-Estvez Consultant for: UCB Pharma, MSD, AbbVie, Novartis, Janssen, Font Ugalde Pilar: None declared, Luis Jurado: None declared